DE69233648D1 - Verwendung von Galanthaminen zur Linderung von Benzodiazepin-Nebenwirkungen - Google Patents

Verwendung von Galanthaminen zur Linderung von Benzodiazepin-Nebenwirkungen

Info

Publication number
DE69233648D1
DE69233648D1 DE69233648T DE69233648T DE69233648D1 DE 69233648 D1 DE69233648 D1 DE 69233648D1 DE 69233648 T DE69233648 T DE 69233648T DE 69233648 T DE69233648 T DE 69233648T DE 69233648 D1 DE69233648 D1 DE 69233648D1
Authority
DE
Germany
Prior art keywords
benzodiazepines
cholinesterase
anxiety
hypnotic
sedative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69233648T
Other languages
English (en)
Other versions
DE69233648T2 (de
Inventor
Ernir Snorasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IS3706A external-priority patent/IS3706A7/is
Priority claimed from DK18292A external-priority patent/DK18292D0/da
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69233648D1 publication Critical patent/DE69233648D1/de
Publication of DE69233648T2 publication Critical patent/DE69233648T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
DE69233648T 1991-05-14 1992-05-14 Verwendung von Galanthaminen zur Linderung von Benzodiazepin-Nebenwirkungen Expired - Fee Related DE69233648T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IS3706A IS3706A7 (is) 1991-05-14 1991-05-14 Notkun á galantamine-hydróbrómíði í geðlæknisfræði
IS370691 1991-07-31
DK18292A DK18292D0 (da) 1992-02-13 1992-02-13 Method of counteracting adverse effects of benzodiazepines
DK18292 1992-02-13

Publications (2)

Publication Number Publication Date
DE69233648D1 true DE69233648D1 (de) 2006-09-28
DE69233648T2 DE69233648T2 (de) 2007-08-09

Family

ID=36746635

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69233648T Expired - Fee Related DE69233648T2 (de) 1991-05-14 1992-05-14 Verwendung von Galanthaminen zur Linderung von Benzodiazepin-Nebenwirkungen
DE69228928T Expired - Fee Related DE69228928T2 (de) 1991-05-14 1992-05-14 Behandlung von schizophrenie mit hilfe von cholinesteraseinhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69228928T Expired - Fee Related DE69228928T2 (de) 1991-05-14 1992-05-14 Behandlung von schizophrenie mit hilfe von cholinesteraseinhibitoren

Country Status (15)

Country Link
US (3) US5336675A (de)
EP (3) EP0584285B1 (de)
JP (2) JP3778923B2 (de)
AT (2) ATE336236T1 (de)
CA (2) CA2103022C (de)
DE (2) DE69233648T2 (de)
DK (2) DK0879596T3 (de)
ES (2) ES2270493T3 (de)
GR (1) GR3030046T3 (de)
IE (2) IE921548A1 (de)
IS (1) IS3863A (de)
NO (2) NO308125B1 (de)
NZ (1) NZ242743A (de)
PT (1) PT879596E (de)
WO (1) WO1992020328A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2210060T3 (es) * 1992-07-24 2004-07-01 The Regents Of The University Of California Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
GB9519268D0 (en) * 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US5736075A (en) * 1996-10-22 1998-04-07 C.J. Associates, Ltd. Method of forming a molded product using a freezing step
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
HUP0103781A3 (en) * 1998-10-16 2003-09-29 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
EP2311441A1 (de) * 1998-11-23 2011-04-20 Bonnie M. Davis Dosisformulierungen für Acetylcholinesterase-inhibitoren
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
DE19857716A1 (de) * 1998-12-15 2000-06-21 Bayer Ag Neue feste Formulierung von Metrifonat
ES2211215T3 (es) 1998-12-24 2004-07-01 Janssen Pharmaceutica N.V. Composicion de galantamina de liberacion controlada.
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
ES2215885T3 (es) * 2000-03-31 2004-10-16 Sanochemia Pharmazeutika Aktiengesellschaft Nuevos derivados y analogos de la galantamina.
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
US6673302B2 (en) 2001-01-24 2004-01-06 Scimed Life Systems, Inc. Wet processing method for catheter balloons
DE10119862A1 (de) 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
CA2358148A1 (en) * 2001-10-03 2003-04-03 Mold-Masters Limited A nozzle
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2003287433A1 (en) * 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
CA2535613A1 (en) * 2003-08-13 2005-02-24 Janssen Pharmaceutica, N.V. Treatment of sleep disorders with cholinesterase inhibitors
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
WO2005115471A2 (en) * 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US9132135B2 (en) 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
JP5710092B2 (ja) * 2004-09-24 2015-04-30 ユニヴァーシティ オヴ メリーランド、バルティモア 有機リン中毒を治療する方法
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
CN101190330A (zh) * 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
AU2008291873B2 (en) * 2007-08-31 2014-05-01 Archimedes Development Limited Non-aqueous pharmaceutical compositions
EP2030610A1 (de) * 2007-08-31 2009-03-04 Archimedes Development Limited Nichtwässrige pharmazeutische Zusammensetzungen
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
AU2021355453A1 (en) * 2020-10-01 2023-05-04 Institute For Basic Science Methods and systems for modifying empathy by modulating type 2 theta oscillations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3856594D1 (de) * 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
IL87861A0 (en) * 1987-10-05 1989-03-31 Pfizer 4-aminopyridine derivatives
JP2699511B2 (ja) * 1988-01-29 1998-01-19 武田薬品工業株式会社 置換アミン類
JP2931986B2 (ja) * 1989-02-17 1999-08-09 武田薬品工業株式会社 アラルキルアミン誘導体
KR940003491B1 (ko) * 1989-08-10 1994-04-23 리히터 게데온 베기에스제티 기아르 알.티 4,4-이중 치환된 피페리딘 유도체와 그 제조방법 및 상기 화합물을 함유하는 약제학적 조성물
DE3927049A1 (de) * 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung

Also Published As

Publication number Publication date
DE69233648T2 (de) 2007-08-09
WO1992020328A3 (en) 1993-04-15
PT879596E (pt) 2007-01-31
NO322137B1 (no) 2006-08-21
JPH06507621A (ja) 1994-09-01
NO934103D0 (no) 1993-11-12
ATE336236T1 (de) 2006-09-15
IE921548A1 (en) 1992-11-18
GR3030046T3 (en) 1999-07-30
NO934103L (no) 1993-11-12
EP0879596A2 (de) 1998-11-25
DE69228928D1 (de) 1999-05-20
NO983939D0 (no) 1998-08-27
EP0584285B1 (de) 1999-04-14
US5589475A (en) 1996-12-31
CA2103022A1 (en) 1992-11-15
AU1873692A (en) 1992-12-30
US5633238A (en) 1997-05-27
DK0879596T3 (da) 2006-12-18
EP0879596B1 (de) 2006-08-16
NZ242743A (en) 1997-02-24
CA2103022C (en) 2006-04-04
CA2468449C (en) 2008-05-13
IE990887A1 (en) 2000-12-13
DE69228928T2 (de) 1999-10-28
EP0879596B8 (de) 2007-05-23
DK0584285T3 (da) 1999-10-25
EP0584285A1 (de) 1994-03-02
ES2270493T3 (es) 2007-04-01
IS3863A (is) 1992-11-15
ES2129450T3 (es) 1999-06-16
JP2002326959A (ja) 2002-11-15
ATE178791T1 (de) 1999-04-15
EP0879596A3 (de) 2000-08-16
AU663086B2 (en) 1995-09-28
WO1992020328A2 (en) 1992-11-26
NO308125B1 (no) 2000-07-31
EP0515302A1 (de) 1992-11-25
US5336675A (en) 1994-08-09
JP3778923B2 (ja) 2006-05-24
NO983939L (no) 1993-11-12
CA2468449A1 (en) 1992-11-26

Similar Documents

Publication Publication Date Title
DE69233648D1 (de) Verwendung von Galanthaminen zur Linderung von Benzodiazepin-Nebenwirkungen
ES2134215T3 (es) Tratamiento de sindromes de fatiga con inhibidores de colinesterasa.
MY140557A (en) Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
ATE229530T1 (de) Tetrahydropyridin-(oder 4-hydroxypiperidin) alkylazole mit sigma und/oder 5ht 1a-rezeptor aktivität
GB9921150D0 (en) Therapeutic agents
DE69715862D1 (de) Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
HK1116184A1 (en) Halogenated pyrazolo [1,5-a]pyrimidines, processes, uses as gaba-a receptors ligand, compositions and intermediates
DE69824195D1 (de) Dipyridoimidazolderivate zur behandlung von störungen des zentralen nervensystems
ATE159018T1 (de) Pyrrolo(2,3-d>azepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
Houlihan et al. Sleep-inducing N-alkyl-5-[m-(trifluoromethyl) phenyl]-5-hydroxy-2-pyrrolidinones and N-alkyl-3-(trifluoromethyl) cinnamamides
DE59103080D1 (de) 9-Amino-2-phenylbicyclo[3.3.1]nonane und 9-Amino-2-phenylbicyclo[3.3.1]-non-2-ene und diese enthaltende therapeutische Mittel.
DK0399653T3 (da) Triazolo(4,5-c)pyridinderivater med antikrampe virkning

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: INVENTOR IS APPLICANT

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee